Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your account with SnapTrade.
On November 3, 2024, Viking released positive trial data for VK2735, the Company’s anti-obesity drug, as part of a presentation at the Obesity Week medical meeting, causing Viking’s stock price to climb 9% during intraday trading on November 4, 2024. However, analysts were quick to note that Viking may face production problems for VK2735, especially for 100mg or higher doses. Analysts at Deutsche Bank stated in a note that scaling up production for the drug “will be costly with capital requirements and expertise beyond what [Eli] Lilly (LLY) and Novo [Nordisk] (NVO) currently have[.]”
Following this news, Viking’s stock price fell over 13% on November 4, 2024.